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http://www.biomedcentral.com/1471-244X/14/50RESEARCH ARTICLE Open AccessCYP1A2 polymorphism −1545C > T (rs2470890) is
associated with increased side effects to clozapine
Merja Viikki1,2*, Olli Kampman1,3, Niko Seppälä4, Nina Mononen5, Terho Lehtimäki5 and Esa Leinonen1,6Abstract
Background: Cytochrome P450 1A2 gene (CYP1A2) polymorphisms have been suggested to be associated with
increased side effects to antipsychotics. However, studies on this are scarce and have been conducted with either
various antipsychotics or only in small samples of patients receiving clozapine. The aim of the present study was to
test for an association between the CYP1A2 −1545C > T (rs2470890) polymorphism and side effects in a larger
sample of patients during long-term clozapine treatment.
Methods: A total of 237 patients receiving clozapine treatment completed the Liverpool University Neuroleptic
Side-Effect Rating Scale (LUNSERS) assessing clozapine-induced side effects. Of these patients, 180 completed the
questionnaire satisfactorily, agreed to provide a blood sample, and were successfully genotyped for the polymorphism.
Results: The TT genotype of CYP1A2 polymorphism −1545C > T (rs2470890) was associated with significantly
more severe side effects during clozapine treatment (p = 0.011). In a subanalysis, all seven types of side effects
(sympathicotonia–tension; depression–anxiety; sedation; orthostatic hypotension; dermal side effects; urinary side
effects; and sexual side effects) appeared numerically (but insignificantly) more severely among TT carriers. In
addition, use of mood stabilizers was more common among patients with the TT genotype (OR = 2.63, p = 0.004).
Conclusions: This study has identified an association between the CYP1A2 polymorphism −1545C > T (rs2470890)
and the occurrence of more severe clozapine side effects. However, these results should be regarded as tentative
and more studies of larger sample sizes will be required to confirm the result.
Keywords: 1545C > T, rs2470890, Clozapine, Side effects, AntipsychoticBackground
Clozapine is the most effective antipsychotic in treatment
refractory schizophrenia [1]. However, its use has been
limited because of the documented infrequent, but serious
side effects such as agranulocytosis. Several other less ser-
ious but more frequent side effects are also noted includ-
ing sedation, weight gain, constipation, hypersalivation,
and hypotension, which may lead to an impaired quality
of life or the need to discontinue clozapine treatment.
Clozapine is metabolized mainly by the cytochrome
P450 enzyme CYP1A2 [2]. The wide inter-individual
variation in the expression and activity of CYP1A2
suggests a role for genetic factors in its control such as
single nucleotide polymorphisms, as well as epigenetic* Correspondence: merja.viikki@gmail.com
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reproduction in any medium, provided the orand environmental factors, including smoking, coffee
drinking, and co-medication [2-4]. The genetic poly-
morphisms of CYP1A2 may affect clozapine clearance
and plasma levels. For instance, the *1 F allele is asso-
ciated with increased enzyme inducibility and the *1C
allele with decreased inducibility [5,6]. In addition, poor
clozapine response and low plasma drug levels have been
found in smokers with the −163A/A genotype [7,8].
CYP1A2 polymorphisms have previously been suggested
to be associated with the side effect response to antipsy-
chotics. An increased tardive dyskinesia severity was
observed in patients with the A allele of the CYP1A2*1C
polymorphism and in another study with CYP1A2 (C→A)
[9,10], while the CYP1A2 −163C > A polymorphism is
associated with clozapine-induced generalized tonic-clonic
seizures [11]. It is postulated that the concomitant absence
of CYP1A2*F and presence of CYP1A2*C could generate
CYP1A2 phenotypes that induce lower mRNA expressiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tolerance [12]. It is possible that the CYP1A2 poly-
morphism −1545C >T could play some role in it. Recently,
Ferrari et al. [13] reported that patients with adverse
drug reactions to clozapine had a higher frequency of
the CYP1A2 low-activity allele and lower CYP1A2
mRNA levels than patients without adverse effects [13].
To the best of our knowledge, however, only one previ-
ous study has reported a possible association between
the −1545C > T (rs2470890) polymorphism and the side
effects of antipsychotics; in this analysis, 1545C > T was
initially associated with tardive dyskinesia, but, after
multiple corrections, this finding was shown to be in-
significant [14].
Interesting findings on the association between CYP1A2
and the side effects of clozapine are scarce, and such stud-
ies have been conducted on fairly small samples. The aim
of the present study, therefore, was to test for an associ-
ation between the CYP1A2 polymorphism −1545C > T
(rs2470890) and side effects in a larger sample of patients
during long-term clozapine treatment.
Methods
Patients
The study included 237 patients with diagnoses of schizo-
phrenia, schizophreniform, schizoaffective, or delusional
disorders according to the International Classification
of Diseases, Tenth Revision (ICD-10). The diagnoses were
set by experienced psychiatrists. All patients were ≥18 years
of age, Caucasian, of Finnish origin, and were receiving
clozapine treatment. Patients who had used clozapine
for less than three months or whose mental state did
not allow reliable self-assessment were excluded from
the study. Of the 237 patients, four were excluded because
of incomplete LUNSERS data (at least 20% of responses
missing). A total of 190 patients (112 men and 78 women)
provided samples for the commercial laboratory meas-
urement of serum clozapine and norclozapine concen-
trations, and 187 patients were successfully genotyped
for −1545C > T (rs2470890).
The study was conducted in three hospital districts in
Western Finland (Satakunta, Pirkanmaa, and Seinäjoki).
The patients were recruited at secondary in- and out-
patient clinics and from sheltered accommodation units.
All participants (n = 237) were asked to complete the
Liverpool University Neuroleptic Side-Effect Rating Scale
(LUNSERS) [15]. This is a self-reported questionnaire of
51 items that assess the intensity of antipsychotic side
effects (0 = not at all, 4 = very much). Forty-one of the
items assess antipsychotic-induced side effects while the
remaining 10 serve as “red herrings” to detect patients
who may be over-reporting symptoms. The reliability and
validity of LUNSERS is well-established [16], although its
validity has not been confirmed in relation to the use ofatypical antipsychotics. Therefore, we performed an ana-
lysis to detect clinically meaningful factors for different
types of side effects. This identified eight clinical factors:
sympathicotonia–tension, depression–anxiety, sedation,
orthostatic hypotension, dermal side effects (rash, sen-
sitivity to sun, new or unusual skin marks or itchy skin),
urinary side effects (difficulty passing urine or passing a
lot of urine), sexual side effects (increased or decreased
sexual drive or difficulty in achieving orgasm), and
menstrual side effects; the latter was omitted from this
study. Information on medical history and duration of
clozapine treatment were collected from medical records.
The study was approved by the local ethics committee.
All participants gave informed consent upon entry to
the study. This study was carried out in accordance with
the code of Ethics of the World Medical Association
(Declaration of Helsinki).
DNA extraction and genotyping
For DNA extraction, 9 ml EDTA-whole blood was drawn
from the participants and stored in a freezer at −20°C.
Genomic DNA was extracted from peripheral blood
leukocytes using the QIAamp®DNA Blood Minikit and
automated biorobot M48 extraction (Qiagen, Hilden,
Germany). Genotyping of rs2470890 was performed using
the Taqman®SNP Genotyping Assay (assay C_1642455_10)
and ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Pipetting
for genotyping was performed on 384 plates by a Tecan
Evo Freedom robot with eight pipetting tips.
Clozapine assay methodology and blood sampling
Clozapine serum concentration measurements were taken
during concomitant routine leukocyte monitoring. The
patients were instructed not to eat or take medications
before the laboratory test, which took place in the
morning. This would then achieve a medication-free
period of 8–14 h prior to serum clozapine concentration
measurement. Clozapine serum levels were determined by
high performance liquid chromatography with ultraviolet
detection (described in detail in [17]).
Statistical analyses
Analysis of variance and t-tests were used for LUNSERS
total scores, factor scores, clozapine dose, and concen-
tration comparisons between different CYP1A2 genotype
groups. Chi-square statistics were used to calculate
differences between frequency of medication use and
CYP1A2 genotypes. The general linear univariate model
(analysis of covariance) was used to determine the ef-
fects of antipsychotic doses and CYP1A2 genotype on
LUNSERS total score. In the model, the antipsychotic
dose was used as a covariate and the CYP1A2 genotype
as a factor. In alternative models, the following factors
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antipsychotic combination, or regular smoking. Power
calculations were made between the LUNSERS total
score and CYP1A2 genotypes according to realized dis-
tributions in these variables. This resulted in a power of
0.803 with a probability (p) < 0.05. All calculations were
performed with SPSS (version 19) and PS (version
3.0.43; [18]) software.Results
A total of 187 patients (110 men [61%] and 70 women
[39%]) were successfully genotyped for the −1545C > T
(rs2470890) polymorphism; of these, 185 had a valid
LUNSERS rating. The mean age was 43.1 (±11.0) years
(range, 20–67 years).
The majority of patients had been receiving clozapine
for over five years (64%). Out of all patients, 34% had
used clozapine for 1–5 years and only 1.9% had used it
for less than a year (3–12 months). The mean time from
the first episode of hospitalization for psychosis until the
start of the study was 17.3 (±10.0) years.
The TT genotype of CYP1A2 polymorphism −1545C > T
(rs2470890) was associated with a significantly greater
side effect frequency during clozapine treatment as mean
LUNSERS scores were 45.1, 36.8, and 37.9 in TT, TC, and
CC carriers, respectively (p = 0.038), and 45.1 vs. 37.1
among TT carriers vs. TC or CC carriers (p = 0.011). In a
subanalysis, all seven types of side effects were found to
be more severe among TT carriers, but this finding was
not statistically significant (Table 1).
The use of mood stabilizers was significantly more
common among patients with the TT genotype than
with TC/CC (OR = 2.63, p = 0.004) (Table 2). Of the
patients, 65% (n = 121) were receiving clozapine mono-
therapy, 24% (n = 45) received a combination of cloza-
pine and second generation antipsychotic therapy (most
often aripiprazole), 9.6% (n = 18) received a combination
of clozapine and first generation antipsychotic therapy,
and 1.6% (n = 3) received both first and second gener-
ation antipsychotic therapy in addition to clozapine. The
clozapine or norclozapine concentration (or their sum
or ratio) did not differ between TT carriers and CC/TC
carriers. In general linear univariate analysis, the
interaction between total antipsychotic dose and the
genotype of CYP1A2 −1545C > T (rs2470890) together ex-
plained 5.0% of the variance in the LUNSERS scale total
score (complete model: p = 0.037, power = 0.682; anti-
psychotic dose: ηp2 = 0.018, p = 0.08; CYP1A2 genotype:
ηp2 = 0.035, p = 0.051). The results of alternative models,
in which clozapine monotherapy, antipsychotic com-
bination, or regular smoking were taken as factors one
at a time were non-significant and the additional factors
had a low predictive power in these models.The allele frequencies in the patient sample were equal
to those in the general population (T = 0.54, C = 0.46),
and there was no gender difference in allele distributions
(men T = 0.56, women T = 0.53; p = 0.55, chi-square test).
The genotypes in the sample were in Hardy-Weinberg
equilibrium (p > 0.10).
Discussion
In the present study, the TT genotype of CYP1A2 poly-
morphism −1545C > T (rs2470890) was associated with
an increased frequency of side effects during clozapine
treatment. In addition, a subanalysis of results showed that
all seven types of side effects (sympathicotonia–tension;
depression–anxiety; sedation; orthostatic hypotension;
dermal side effects; urinary side effects; and sexual side
effects) were more severe among TT carriers, but this
finding was not statistically significant. Previous studies
reported that different CYP1A2 polymorphisms were
associated with adverse effects of antipsychotics; although,
to our knowledge, only one has assessed the association
between the −1545C > T (rs2470890) polymorphism and
antipsychotic side effects [14]. Moreover, in this study, an
excess of the T allele was observed among patients with
tardive dyskinesia during initial analysis, but this was later
revised after multiple corrections to be an insignificant
finding [14]. Our results are in line with the initial analysis
of this earlier work.
In previous studies, higher plasma concentrations
of clozapine and its metabolite N-desmethylclozapine
have been reported in patients with two CYP1A2
variants associated with reduced enzyme activity
(−3860A, −2467del, −163C, −739G, and/or −729T) com-
pared with those with one or no variants [19]. Although
it might be expected that the higher frequency of side
effects among TT carriers observed in the present study
could be explained by higher plasma concentrations of
clozapine in those individuals, we found no difference
in clozapine or norclozapine concentrations (or their
sums or ratios) between TT carriers and CC/TC carriers.
Likewise, use of other co-medication, such as selective
serotonin uptake inhibitors (SSRIs) and serotonin nor-
epinephrine reuptake inhibitors (SNRIs) and other anti-
psychotics may have contributed to the frequency or
severity of side effects. However, the use of SSRIs, SNRIs,
and the total dose of all antipsychotics did not differ
between patients with the TT genotype and those with
CC/TC genotypes.
Smoking is a known CYP1A2 inducer, and lower plasma
concentrations of clozapine have previously been detected
in smokers with the −163A/A genotype [7,8,20]). Since
the C allele of CYP1A2*1 F, which is in complete linkage
disequilibrium with the C allele of CYP1A2 1545C > T
(exon) [14], leads to decreased inducibility among smokers,
the C allele of rs2470890 would also be expected to be
Table 1 LUNSERS scores (mean ± SD) and frequency of side effects according to genotype and in the total population
Symptom LUNSERS scores mean (±SD)
Frequency of the symptom %
TT (n=54) TC (n=96) CC (n=35) Total (n=185)
Sympathicotonia-tension 7.35 (±4.87) 6.54 (±4.77) 6.69 (±5.61) 6.81 (±4.95)
88.9% 92.7% 82.9% 89.7%
Depression-anxiety 9.65 (± 5.94) 8.11 (±4.55) 8.14 (±5.14) 8.57 (±5.12)
90.7% 91.7% 88.6 90.8%
Sedation 5.13 (± 3.28) 4.81 (±2.65) 4.97 (±2.83) 4.93 (±2.87)
88.9% 96.9% 91.2% 93.5%
Orthostatic hypotension 3.41 (±2.67) 2.79 (±2.51) 2.82 (±2.86) 2.98 (±2.63)
81.5% 75.0% 70.6% 76.1%
Dermal side effects 1.11 (±1.46) 1.09 (±1.62) 0.97 (±1.43) 1.08 (±1.53)
47.3% 40.6% 38.2 42.2%
Sexual side effects 1.96 (±2.23) 1.61 (±1.99) 1.73 (±1.94) 1.74 (±2.05)
61.8% 54.2% 59.5% 57.4%
Urinary side effects 2.09 (±1.94) 1.45 (±1.90) 1.80 (±2.25) 1.70 (±1.99)
74.5% 49.0% 54.1% 57.4%
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ing was more common among patients with the TT
genotype in the present study, this would explain why
such individuals require higher clozapine doses yet serum
clozapine concentrations are not increased. However,
smoking status was similar in all patients. Another lifestyle
factor that could explain the difference in CYP1A2 metab-
olism is coffee drinking. It has been suggested that caffeine
inhibits clozapine metabolism and increases serum cloza-
pine concentrations [21]. Although caffeine intake was not
assessed in the present study, the effect of drinking instant
coffee on serum clozapine concentrations was reported to
be of minor clinical relevance in most cases within a smallTable 2 Comparisons between CYP1A2 1545C > T (rs2470890)
Patients TT (n
Males 32 (59
Regular smokers 29 (52
Antipsychotic co-medication 18 (33
Atypical 14 (25
Conventional 2 (3.
Both 2 (3.
Mood stabilizer adjuvant therapy 24 (44
SSRI/SNRI adjuvant therapy 21 (38
Clozapine + norclozapine serum level mol/l (mean+SD) 2.21+
Clozapine/norclozapine ratio (mean+SD) 1.68+
Clozapine dose/serum level ratio (mean+SD) 441+
Clozapine dose mg (mean+SD) 431+
Antipsychotic total dose mg* (mean+SD) 971+
*In chlorpromazine equivalents.sample of Finnish patients [22]. Carbamazepine, used to
control epileptic seizure, also induces CYP1A2 [23]. How-
ever, it was seldom used in our patients and there was no
difference in the frequency of carbamazepine use between
TTcarriers and CC/TC carriers.
The second finding of the present study was that
mood stabilizer use was more common among individ-
uals with the TT genotype than CT or CC carriers. The
reason for this is unclear, although it is possible that the
TT carriers who experienced more adverse effects also
complained more about other symptoms such as anxiety,
depression, or mood swings. This may have resulted
in the administration of a mood stabilizer, and thisTT and C-carrier patient groups
=54) TC/CC (n=133) PP between groups
.3%) 78 (58.6%) NS
.7%) 65 (49.6%) NS
.3%) 48 (36.1%) NS
.9%) 31 (23.3%)
7%) 16 (12.0%)
7%) 1 (0.8%)
.4%) 31 (23.3%) 0.004
.9%) 46 (34.6%) NS
0.98 2.45+1.36 0.20
0.60 1.71+0.59 0.78
195 405+309 0.44
132 390+150 0.078
380 883+389 0.17
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verity of adverse effects. It is also conceivable that the
TT genotype is associated with CYP1A2 induction, thus
weakening the antipsychotic response and requiring the
addition of a mood stabilizer. However, the most com-
mon reasons for adding a mood stabilizer were to pre-
vent seizures, as clozapine increases their risk, and to
reduce aggression. In some cases, mood stabilizer use
was indicated because the primary disease was schizoaf-
fective disorder. However, only 6% (n = 14) of patients
had a diagnosis of schizophreniform, schizoaffective, or
delusional disorders. It was not possible to analyze these
disorders separately, however, and this can be regarded
as a study limitation. The most commonly added mood
stabilizer in the present study was valproic acid.
The assay for clozapine measurement provides excel-
lent precision and accuracy. However, it has been sug-
gested that the thermal instability of clozapine-N-oxide
represents a concern regarding the potential for over-
estimation of clozapine [24]. When exposed to heat or
to alkaline conditions clozapine-N-oxide again yields
clozapine. However, this was unlikely in the present
study because special efforts were taken during sample
workup and chromatographic analysis to avoid overesti-
mation of clozapine.
The main limitation of our study was its fairly small
sample size, which markedly reduces the statistical power
to detect small or moderate effects. However, we recruited
almost all patients within the geographical area who were
receiving clozapine treatment and able to give their in-
formed consent. A second limitation is that LUNSERS
is a self-reported questionnaire that requires items to
be rated from “not at all” to “very much” with no descrip-
tion or criteria. This could have affected reliability. More-
over, the reported side effects were not systematically
confirmed by clinicians or compared with clinical records,
and we lacked data on which side effects led to reduction
of the dose. Nevertheless, the reliability and validity of
LUNSERS is well-established [16]. Most patients had been
on clozapine for over 5 years, so there were no cases
of agranulocytosis/neutropenia, which usually develops
during the first 3 months of clozapine use; we also only
included patients who had been on clozapine for at
least 3 months. Weight gain was a common side effect,
with 56% of patients reporting this although we did not
analyze it here as this will be presented in a separate
analysis. Lack of data on caffeine intake is also a limitation
of the present study. The results of alternative statistical
models, with clozapine monotherapy or antipsychotic com-
binations as individual factors, were non-significant and the
additional factors had a low predictive power in these
models. Finally, the lack of patient mean positive and
negative syndrome scale data meant that we could not
assess whether −1545C > T was related to lack of response.Conclusions
The present findings suggest an association between the
TT genotype of the CYP1A2 polymorphism −1545C > T
(rs2470890) and side effects of clozapine. However,
these findings should be regarded as tentative and more
studies with larger samples will be required to confirm
the results.
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